Sihuan Pharmaceutical Invests in Phase I Fund of Ascendum Capital Life Technology to Expand its Strategy in Development of Innovative Drugs

HONG KONG, Oct. 20, 2020 /PRNewswire/ -- On 20 October 2020, Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") announced that its participation in the investment of Phase I Fund of Ascendum Capital Life Technology. The Company looks forward to expand its resources in the development of innovative drugs and accelerate the introduction of overseas innovative drugs in China, strengthen the its resources and development of its international product pipeline and accelerate its product innovation and internationalization. Sihuan Pharmaceutical's investment and participation in the fund provides valuable support for Ascendum Capital's future development of medical devices and biopharmaceuticals. This cooperation allows both parties to share resources in a timely manner as it creates a win-win situation.Sihuan Pharmaceutical was established in 2001. After nearly 20 years pursuing research and development, the company has grown into a large listed pharmaceutical enterprise with an integrated R&D, production and sales system. It is one of the largest suppliers of cardiovascular and cerebrovascular prescription drugs in China. Currently, Sihuan Pharmaceutical's R&D product pipeline has a total of 80 therapeutics, including innovative drugs with small molecule targets (14 items), biologic drugs with huge market potential (13 items), and generic drugs with high technical barriers (53 items).In the R&D pipeline, Sihuan Pharmaceutical's drug portfolio targets major therapeutic areas, including oncology, metabolism, chronic diseases, neuropsychiatric, digestive diseases, anti-infectives, and cardiovascular and cerebrovascular diseases. More than 10 drugs have entered phase III clinical trial or are in the approved production stage. Sihuan Pharmaceutical has a high-quality pre-clinical R&D team of nearly 200 people, including a number of senior scientists with extensive industry experience in internationally renowned pharmaceutical enterprises. The company also has a 200-person clinical development team, which includes more than 70 doctors, masters and overseas returnees. The company features strong research and development capabilities.Currently, Sihuan Pharmaceutical has a global business development center in the United States that focuses on developing first-in-class oncology, diabetes therapeutics as well as other therapeutic areas with huge clinical needs. The Company also employs international experts to expand and manage business projects in China and abroad. These international experts supportA Sihuan Pharmaceutical's global business and accelerate the introduction and deployment of international projects.In early 2014, Sihuan Pharmaceuticals established a partnership with South Korea's leading medical aesthetics manufacturer Hugel and codeveloped botulinum toxin and filler products, which will contribute to new business growth. The botulinum toxin product is expected to receive approval before the end of this year, making it the first and only South Korean botulinum toxin product to be approved in China, Sihuan will act as the sole agent for this product.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Ноябрь 2020    »